SYNDESI THERAPEUTICS
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
SYNDESI THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Louvain-la-neuve, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.syndesitherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
+32 10 280 238
Email Addresses:
[email protected]
Total Funding:
26.2 M EUR
Technology used in webpage:
SPF Microsoft Azure DNS Cisco Ironport Cloud
Similar Organizations
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Novo Holdings
Novo Holdings investment in Series A - Syndesi Therapeutics
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series A - Syndesi Therapeutics
V-Bio Ventures
V-Bio Ventures investment in Series A - Syndesi Therapeutics
Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC investment in Series A - Syndesi Therapeutics
UCB Ventures
UCB Ventures investment in Series A - Syndesi Therapeutics
S.R.I.W.
S.R.I.W. investment in Series A - Syndesi Therapeutics
Vives Louvain Technology Fund
Vives Louvain Technology Fund investment in Series A - Syndesi Therapeutics
WING by Digital Wallonia
WING by Digital Wallonia investment in Grant - Syndesi Therapeutics
Vives Louvain Technology Fund
Vives Louvain Technology Fund investment in Series A - Syndesi Therapeutics
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series A - Syndesi Therapeutics
Official Site Inspections
http://www.syndesitherapeutics.com
- Host name: 159.180.132.176
- IP address: 159.180.132.176
- Location: North Chicago United States
- Latitude: 42.325
- Longitude: -87.8561
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60064
More informations about "Syndesi Therapeutics"
Syndesi Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +32 10 280 238 Syndesi Therapeutics is developing molecules that uniquely modulate the …See details»
Syndesi Therapeutics Company Profile 2024: Valuation, Investors ...
Syndesi Therapeutics General Information Description. Developer of drug molecules designed to treat cognitive impairment. The company's drugs can modulate the synaptic vesicle protein to …See details»
Syndesi Therapeutics Information - RocketReach
Syndesitherapeutics.com; View Similar People. Related Companies SYnAbs. 9 $11m Ars Statistica. 1 e-Proteins. 3 $5m BioXtract. 3 $4m LaCAR MDX Technologies. 44 $2m Hyloris …See details»
Syndesi Therapeutics - Overview, News & Similar companies
Popular Searches Syndesi Therapeutics SA Syndesi LLC Syndesi Therapeutics Syndesitherapeutics SIC Code 28,283 NAICS Code 32,325 Show more. View Email Formats …See details»
Syndesi Therapeutics Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Syndesi Therapeutics of Wavre. Get the latest business insights from Dun & Bradstreet.See details»
Syndesi Therapeutics - Company Profile - Tracxn
Sep 8, 2024 Syndesi Therapeutics - Developer of small molecule for treating Alzheimer's disease. Acquired by AbbVie. Raised a total funding of $21.1M over 2 rounds from 7 investors. …See details»
Syndesi Therapeutics Company Profile - Craft
Syndesi Therapeutics is a biotech company developing molecules. It focuses on creating molecules for regulating synaptic transmission and treating disorders with cognitive impairment.See details»
Syndesi Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
View Syndesi Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Syndesi Therapeutics SA - Drug pipelines, Patents, Clinical trials ...
Explore Syndesi Therapeutics SA with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 4 news, Drug:Plosaracetam.See details»
Nextsource | Company Profile | Syndesi Therapeutics
Explore the company profile of Syndesi Therapeutics (syndesitherapeutics.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
Syndesi Therapeutics S.A. - Life-Sciences-Europe.com
Feb 1, 2018 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry …See details»
Syndesi - VentureRadar
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show... ... Find out more about ...See details»
Syndesi Therapeutics - Sopartec
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. …See details»
UCB and investor syndicate led by Novo Seeds launch Syndesi ...
Feb 1, 2018 Syndesi Therapeutics (www.syndesitherapeutics.com) has been established at the Centre d’Entreprises et d’Innovation (CEI) in Louvain-la-Neuve and will have a presence at the …See details»
Syndesi Therapeutics - VIVES fund
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. …See details»
Syndesi Therapeutics Company Profile - Selligence
[email protected]: Description: Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic …See details»
Syndesi Therapeutics CEO and Key Executive Team | Craft.co
Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. Other executives include John Kemp, Chief Scientific Officer; Torsten Madsen, Chief Medical Officer and 4 others. See …See details»
Syndesi Therapeutics - EU-Startups
Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. Syndesi has an exclusive license to its platform …See details»
V-Bio Ventures’ portfolio company Syndesi Therapeutics acquired …
Mar 2, 2022 “There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases,” said Tom Hudson, …See details»
Syndesis Health Company Profile 2024: Valuation, Funding
Syndesis Health General Information Description. Operator of a biotechnology research company intended to offer life sciences research and innovation for biotechs, pharma, and research …See details»